Analysis of systemic symptoms in COVID-19
 
More details
Hide details
1
Katedra i Oddział Kliniczny Otorynolaryngologii i Onkologii Laryngologicznej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
 
2
Oddział Laryngologii i Onkologii Laryngologicznej, Górnośląskie Centrum Medyczne im. prof. Leszka Gieca Śląskiego Uniwersytetu Medycznego w Katowicach
 
3
Studenckie Koło Naukowe przy Katedrze i Oddziale Klinicznym Otorynolaryngologii i Onkologii Laryngologicznej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
 
 
Corresponding author
Adam S. Dadok   

Katedra i Oddział Kliniczny Otorynolaryngologii i Onkologii Laryngologicznej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, ul. Marii Skłodowskiej-Curie 10, 41-800 Zabrze
 
 
Ann. Acad. Med. Siles. 2022;76:86-90
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
COVID-19 (coronavirus disease 2019), a disease caused by SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection, may have a more or less severe course. The aim of this study was to analyse the symptoms which occurred in a group of people who tested positively for the presence of the genetic material of the virus

Material and methods:
The analysis was based on the results of 337 questionnaires collected from Polish patients – 185 (55%) females and 152 (45%) males aged 18–86. The questionnaire included 26 questions, of which 11 were related to systemic symptoms. The frequency of their occurrence and their severity were determined according to Visual Analogue Scale (VAS).

Results:
The most common symptoms that occurred in over 50% of the respondents included: general weakness (91% of the respondents, severity of 6.25 on VAS), musculoskeletal pain (77%, VAS 5.67), headache (65%, VAS 5.37) and cough (56%, VAS 4.76). Runny nose, fever above 38℃ and sore throat were less common and occurred in 39% of the subjects. The least frequent symptoms were diarrhoea (23%), skin lesions (7%) and vomiting (3%). When determining the correlation coefficient, it was also found that dyspnoea occurred most often with general weakness (r = 1), whereas general weakness was less frequently associated with musculoskeletal pain (r = 0.8). No statistically significant relationships were found between the frequency of the symptoms and age, gender or the presence of comorbidities in the respondents.

Conclusions:
The observations showed that in the analysed group of people with SARS-CoV-2 infection, the disease had a mild-to-moderate course. General weakness, musculoskeletal pain, cough, and upper respiratory tract infection symptoms were the most common.

 
REFERENCES (26)
1.
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020; 5(4): 536–544, doi: 10.1038/s41564-020-0695-z.
 
2.
Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N. Engl. J. Med. 2020; 382(13): 1199–1207, doi: 10.1056/NEJMoa2001316.
 
3.
Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 2020; 382(8): 727–733, doi: 10.1056/NEJMoa2001017.
 
4.
World Health Organization. Origin of SARS-CoV-2, 26 March 2020. Avalaible at: https://apps.who.int/iris/hand... [accessed on 20 June 2020].
 
5.
Pierwszy przypadek koronawirusa w Polsce. Portal gov.pl [online], 04.03.2020. Avalaible at: https://www.gov.pl/web/zdrowie... [accessed on 20 June 2020).
 
6.
WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. World Health Organization [online], 11 March 2020. Available at: https://www.who.int/director-g... [accessed on 20 June 2020].
 
7.
Coronavirus disease (COVID-2019) situation reports. Word Health Organization [online]. Available at: https://covid19.who.int/ [accessed on 20 June 2020].
 
8.
Frame B., Hemmings A.D. Coronavirus at the end of the world: Antarctica matters. Soc. Sci. Humanit. Open 2020; 2(1): 100054, doi: 10.1016/j.ssaho.2020.100054.
 
9.
Lotfi M., Hamblin M.R., Rezaei N. COVID-19: Transmission, prevention, and potential therapeutic opportunities. Clin. Chim. Acta 2020; 508: 254–266, doi: 10.1016/j.cca.2020.05.044.
 
10.
Bi Q., Wu Y., Mei S., Ye C., Zou X., Zhang Z. et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study [published correction appears in Lancet Infect. Dis. 2020; 20(7): e148]. Lancet Infect. Dis. 2020; 20(8): 911–919, doi: 10.1016/S1473-3099(20)30287-5.
 
11.
Güner R., Hasanoğlu I., Aktaş F. COVID-19: Prevention and control measures in community. Turk. J. Med. Sci. 2020; 50(3): 571–577, doi: 10.3906/sag-2004-146.
 
12.
Pascarella G., Strumia A., Piliego C., Bruno F., Del Buono R., Costa F. et al. COVID-19 diagnosis and management: a comprehensive review. J. Intern. Med. 2020; 288(2): 192–206, doi: 10.1111/joim.13091.
 
13.
Goudouris E.S. Laboratory diagnosis of COVID-19. J. Pediatr. 2021; 97(1): 7–12, doi: 10.1016/j.jped.2020.08.001.
 
14.
Abbasi-Oshaghi E., Mirzaei F., Farahani F., Khodadadi I., Tayebinia H. Diagnosis and treatment of coronavirus disease 2019 (COVID-19): Laboratory, PCR, and chest CT imaging findings. Int. J. Surg. 2020; 79: 143–153, doi: 10.1016/j.ijsu.2020.05.018.
 
15.
Oran D.P., Topol E.J. Prevalence of asymptomatic SARS-CoV-2 infection: a narrative review. Ann. Intern. Med. 2020; 173(5): 362–367, doi: 10.7326/M20-3012.
 
16.
Alimohamadi Y., Sepandi M., Taghdir M., Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J. Prev. Med. Hyg. 2020; 61(3): E304–E312, doi: 10.15167/2421-4248/jpmh2020.61.3.1530.
 
17.
Coronavirus disease (COVID-19). World Health Organization [online]. Available at: https://www.who.int/health-top... [accessed on 20 June 2020].
 
18.
Wan S., Xiang Y., Fang W., Zheng Y., Li B., Hu Y. et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J. Med. Virol. 2020; 92(7): 797–806, doi: 10.1002/jmv.25783.
 
19.
Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395(10223): 507–513, doi: 10.1016/S0140-6736(20)30211-7.
 
20.
Grant M.C., Geoghegan L., Arbyn M., Mohammed Z., McGuinness L., Clarke E.L. et al. The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One 2020; 15(6): e0234765, doi: 10.1371/journal.pone.0234765.
 
21.
Lechien J.R., Chiesa-Estomba C.M., Place S., Van Laethem Y., Cabaraux P., Mat Q. et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J. Intern. Med. 2020; 288(3): 335–344, doi: 10.1111/joim.13089.
 
22.
Jungreis I., Sealfon R., Kellis M. SARS-CoV-2 gene content and COVID-19 mutation impact by comparing 44 Sarbecovirus genomes. Nat. Commun. 2021; 12(1): 2642, doi: 10.1038/s41467-021-22905-7.
 
23.
Baj J., Karakuła-Juchnowicz H., Teresiński G., Buszewicz G., Ciesielka M., Sitarz R. et al. COVID-19: Specific and non-specific clinical manifestations and symptoms: The current state of knowledge. J. Clin. Med. 2020; 9(6): 1753, doi: 10.3390/jcm9061753.
 
24.
Cao Y., Li L., Feng Z., Wan S., Huang P., Sun X. et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020; 6: 11, doi: 10.1038/s41421-020-0147-1.
 
25.
Megyeri K., Dernovics Á., Al-Luhaibi Z.I.I., Rosztóczy A. COVID-19-associated diarrhea. World J. Gastroenterol. 2021; 27(23): 3208–3222, doi: 10.3748/wjg.v27.i23.3208.
 
26.
de Oliveira A.P., Lopes A.L.F., Pacheco G., de Sá Guimarães Nolêto I.R., Nicolau L.A.D., Medeiros J.V.R. Premises among SARS-CoV-2, dysbiosis and diarrhea: Walking through the ACE2/mTOR/autophagy route. Med. Hypotheses 2020; 144: 110243, doi: 10.1016/j.mehy.2020.110243.
 
eISSN:1734-025X
Journals System - logo
Scroll to top